Recent announcements
POINT Biopharma adds a COO, Further Strengthens Leadership Team, and Announces Additional Board and Leadership Changes
Justyna Kelly promoted to COO, Dr. Robin Hallett promoted to VP, Discovery and Translational Sciences, Dr. Sherin Al-Safadi to join as VP Medical Affairs, and Michael Gottlieb (CCO) to depart the Company to pursue other opportunities. Jonathan Ross Goodman elected Lead Independent Director of the Board of Directors.
POINT Biopharma Licenses Innovative Lu-177 Production Technology from SCK CEN (Belgian Nuclear Research Center)
POINT Biopharma Global Inc. and Studiecentrum voor Kernenergie/Centre d’Etude de l’Energie Nucléaire, also known as the Belgian Nuclear Research Center (“SCK CEN”) today announced a technology license agreement for Lu-177 purification technology to accelerate POINT’s in-house no-carrier-added lutetium-177 (n.c.a. Lu-177) production program.
POINT Biopharma to Host Virtual Education Event on December 6, 2021
POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations. Register online at https://hub.pointbiopharma.com/dec2021.
POINT Biopharma Reports Third Quarter 2021 Financial Results and Provides Business Update
POINT Biopharma Reports Third Quarter 2021 Financial Results and Provides Business Update: Initiated randomization phase of Phase 3 SPLASH study of PNT2002 in patients with metastatic castration-resistant prostate cancer (mCRPC)...
POINT Biopharma and IONETIX Announce Ac-225 Supply Agreement
POINT Biopharma Global Inc.(NASDAQ: PNT) and IONETIX Corp announced today a long-term supply agreement for actinium-225 (Ac-225) to support POINT’s validation, drug development, and clinical trials for Ac-225-based radiopharmaceuticals.
POINT Biopharma and Kinectrics Announce Yb-176 Supply Agreement Enabling North American Production of n.c.a. Lu-177
POINT Biopharma Global Inc. (NASDAQ: PNT) and Kinectrics Inc. announced today a long-term supply agreement for Ytterbium-176 (Yb-176) to support POINT’s in-house no-carrier added Lutetium-177 (n.c.a. Lu-177) production program.
POINT Biopharma joins Tri-party Collaboration to Advance Ga-68 Imaging Products
ARTMS has entered into a tri-party co-operation with fellow industry leaders, POINT Biopharma and the Canadian Molecular Imaging Probe Consortium (CanProbe), a joint venture between the Centre for Probe Development...
POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor
Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models. Initiation of a Phase 1 therapeutic clinical trial planned for 1H2022